The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells

Previous studies have suggested that histone methylation can modulate carcinogenesis and cancer progression. For instance, the histone methyltransferase SET and MYND domain containing 2 (SMYD2) is overexpressed in several types of cancer tissue. The aim of the present study was to determine whether...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Kojima, Machiko, Sone, Kenbun, Oda, Katsutoshi, Hamamoto, Ryuji, Kaneko, Syuzo, Oki, Shinya, Kukita, Asako, Kawata, Akira, Honjoh, Harunori, Kawata, Yoshiko, Kashiyama, Tomoko, Sato, Masakazu, Taguchi, Ayumi, Miyamoto, Yuichiro, Tanikawa, Michihiro, Tsuruga, Tetsushi, Nagasaka, Kazunori, Wada-Hiraike, Osamu, Osuga, Yutaka, Fujii, Tomoyuki
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2020
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7471656/
https://ncbi.nlm.nih.gov/pubmed/32934721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.12014
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars